Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      USFDA completes Ghaziabad plant inspection, no observations issued: Unichem

      USFDA completes Ghaziabad plant inspection, no observations issued: Unichem

      Ruby Khatun Khatun22 April 2018 10:15 AM IST
      New Delhi: Drug firm Unichem Laboratories said it has not received any observations from the US health regulator after completion of inspection of its...
      FDA approves Rigel Pharmaceuticals drug for rare bleeding disorder

      FDA approves Rigel Pharmaceuticals drug for rare bleeding disorder

      Ruby Khatun Khatun22 April 2018 10:00 AM IST
      The U.S. Food and Drug Administration (FDA) on Tuesday approved Rigel Pharmaceuticals Inc’s treatment for a rare bleeding disorder.Rigel’s Tavalisse...
      Experts query case for GlaxoSmithKlines new 3-in-1 lung drug

      Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

      Ruby Khatun Khatun22 April 2018 9:45 AM IST
      LONDON: Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company...
      344 FDC Drugs Issue: DGHS extends timeline for response

      344 FDC Drugs Issue: DGHS extends timeline for response

      Ruby Khatun Khatun22 April 2018 9:30 AM IST
      New Delhi: Through a recent notification, Directorate General of Health Services taking in of the directions of the Hon'ble Supreme Court of India in...
      Abbott sticks to earlier forecasts, disappoints investors

      Abbott sticks to earlier forecasts, disappoints investors

      Ruby Khatun Khatun22 April 2018 9:30 AM IST
      Abbott Laboratories' just beat expectations for first-quarter profits and revenue but stuck to a full-year profit forecast some investors had expected...
      Fortis board decides to consider only Binding Offers, Faces Backlash

      Fortis board decides to consider only Binding Offers, Faces Backlash

      Ruby Khatun Khatun21 April 2018 4:33 PM IST
      New Delhi: While the many offers are available on the table of Fortis, the board considering the offers has decided to take consideration only of...
      Cognizant completes acquisition of Bolder Healthcare Solutions

      Cognizant completes acquisition of Bolder Healthcare Solutions

      Ruby Khatun Khatun21 April 2018 11:00 AM IST
      New Delhi: IT firm Cognizant said it has completed the acquisition of Bolder Healthcare Solutions, a provider of revenue cycle management (RCM)...
      P&G to acquire 51.8 percent stake in Merck in India for Rs 1,290 crore

      P&G to acquire 51.8 percent stake in Merck in India for Rs 1,290 crore

      Ruby Khatun Khatun21 April 2018 10:30 AM IST
      New Delhi: Procter & Gamble (P&G) will acquire 51.80 percent stake for Rs 1,289.88 crore in India listed drug firm Merck Ltd as part of a...
      Top Indian Pharma formulators eyeing OTC market: Report

      Top Indian Pharma formulators eyeing OTC market: Report

      Ruby Khatun Khatun21 April 2018 10:30 AM IST
      Mumbai: Indian pharmaceutical formulators are expected to continue to make investments in consumer healthcare, wellness products, and traditional OTC...
      Zydus gets USFDA nod for drug used treat knee osteoarthritis

      Zydus gets USFDA nod for drug used treat knee osteoarthritis

      Ruby Khatun Khatun21 April 2018 10:15 AM IST
      New Delhi: Zydus Cadila has received final approval from the US health regulator to market Diclofenac Sodium Topical Solution, used for treating signs...
      AstraZeneca wins US approval for 1st-line use of lung cancer drug

      AstraZeneca wins US approval for 1st-line use of lung cancer drug

      Ruby Khatun Khatun21 April 2018 9:45 AM IST
      U.S. regulators have expanded use of AstraZeneca’s lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic...
      GSK flags pharma Merger and Acquisition ambitions by poaching Roche deal-maker

      GSK flags pharma Merger and Acquisition ambitions by poaching Roche deal-maker

      Ruby Khatun Khatun21 April 2018 9:30 AM IST
      LONDON: GlaxoSmithKline (GSK) signaled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche’s Genentech...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok